carbamazepine has been researched along with Machado-Joseph Disease in 2 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Machado-Joseph Disease: A dominantly-inherited ATAXIA first described in people of Azorean and Portuguese descent, and subsequently identified in Brazil, Japan, China, and Australia. This disorder is classified as one of the SPINOCEREBELLAR ATAXIAS (Type 3) and has been associated with a mutation of the MJD1 gene on chromosome 14. Clinical features include progressive ataxia, DYSARTHRIA, postural instability, nystagmus, eyelid retraction, and facial FASCICULATIONS. DYSTONIA is prominent in younger patients (referred to as Type I Machado-Joseph Disease). Type II features ataxia and ocular signs; Type III features MUSCULAR ATROPHY and a sensorimotor neuropathy; and Type IV features extrapyramidal signs combined with a sensorimotor neuropathy. (From Clin Neurosci 1995;3(1):17-22; Ann Neurol 1998 Mar;43(3):288-96)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), is the most common autosomal dominantly-inherited ataxia worldwide and is characterised by the accumulation of mutant ataxin-3 (mutATXN3) in different brain regions, leading to neurodegeneration." | 5.72 | The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease. ( Carmo-Silva, S; Codêsso, JM; França, MC; Martinez, ARM; Nóbrega, C; Pereira de Almeida, L; Silva, P; Vasconcelos-Ferreira, A, 2022) |
| "Machado-Joseph disease (MJD), or spinocerebellar ataxia type 3 (SCA3), is the most common autosomal dominantly-inherited ataxia worldwide and is characterised by the accumulation of mutant ataxin-3 (mutATXN3) in different brain regions, leading to neurodegeneration." | 1.72 | The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease. ( Carmo-Silva, S; Codêsso, JM; França, MC; Martinez, ARM; Nóbrega, C; Pereira de Almeida, L; Silva, P; Vasconcelos-Ferreira, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vasconcelos-Ferreira, A | 1 |
| Carmo-Silva, S | 1 |
| Codêsso, JM | 1 |
| Silva, P | 1 |
| Martinez, ARM | 1 |
| França, MC | 1 |
| Nóbrega, C | 1 |
| Pereira de Almeida, L | 1 |
| Kanai, K | 1 |
| Kuwabara, S | 1 |
2 other studies available for carbamazepine and Machado-Joseph Disease
| Article | Year |
|---|---|
The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado-Joseph disease.
Topics: Animals; Ataxin-3; Autophagy; Carbamazepine; Humans; Machado-Joseph Disease; Mice; Motor Disorders; | 2022 |
Motor nerve hyperexcitability and muscle cramps in Machado-Joseph disease.
Topics: Anticonvulsants; Axons; Carbamazepine; Diagnosis, Differential; Disease Progression; Growth Cones; H | 2009 |